Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Qiagen NV(QGEN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for QGEN
11/06/2026: QGEN (3-star) is a STRONG-BUY. BUY for 95 days. Simulated Profits (30.42%). Updated daily EoD!
Qiagen NV is a specialized provider of life science research and molecular diagnostic tools, known for its foundational sample preparation technology. The company has a leading position in high-margin, recurring-revenue consumable kits and has successfully expanded into syndromic and digital PCR diagnostics. Its primary growth opportunity lies in capitalizing on the shift toward precision medicine and decentralized clinical testing. However, it faces execution risks in integrating diverse acquisitions and intense competition from larger, well-capitalized life science conglomerates. Qiagen is best suited for growth-oriented investors looking for stable exposure to genomics trends, with the caveat that it does not pay a cash dividend.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Qiagen offers exposure to high-growth molecular diagnostics and genomics trends. |
| Momentum investor | Mixed fit | Momentum depends on the success of new product cycles like QIAcuity and diagnostic adoption. |
| Value investor | Mixed fit | Valuation is often tied to biotech multiples, which can fluctuate based on broader market sentiment. |
| Dividend investor | Weak fit | Qiagen does not pay a cash dividend, making it unsuitable for income-focused portfolios. |
| Low-risk investor | Medium | While established, the stock is subject to industry-specific regulatory and innovation risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | Biotech and diagnostics stocks often experience volatility tied to R&D outcomes and news cycles. |
| Valuation risk | Medium | Earnings multiples can be sensitive to shifts in interest rates and sector-wide growth expectations. |
| Competition risk (diagnostics/tools) | High | Facing well-capitalized giants like TMO and DHR makes it difficult to maintain market share without constant innovation. |
| Business quality | Strong | The high recurring revenue from consumables provides a stable foundation for the business. |
| Dividend income | Low / none | Investors should not rely on the stock for cash income. |
| Execution risk | Medium | Successfully integrating new diagnostic platforms into clinical workflows is essential for long-term growth. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 12.3% | Avg. Invested days 41 | Today’s Advisory Regular Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 11/06/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.39B USD | Price to earnings Ratio 27.21 | 1Y Target Price 49.02 |
Price to earnings Ratio 27.21 | 1Y Target Price 49.02 | ||
Volume (30-day avg) 5.0M shares | Beta 0.56 | 52 Weeks Range 32.24 - 57.30 | Updated Date 11/08/2026 |
52 Weeks Range 32.24 - 57.30 | Updated Date 11/08/2026 | ||
Dividends yield (FY) 0.69% | Basic EPS (TTM) 1.85 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Consumables | Kits for purification and assays; provides recurring revenue. | This is the 'razor-and-blade' model where labs continuously buy these kits for their tests. |
| Instruments | Automated platforms like QIAstat-Dx and QIAcuity. | These machines create the installed base that drives ongoing demand for consumables. |
| Geography | Operations in Americas, EMEA, and Asia-Pacific. | Global diversification helps mitigate regional economic or regulatory downturns. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-04 | When After Market | Estimate 0.63 | Actual 0.65 |
Profitability
Profit Margin 18.2% | Operating Margin (TTM) 27.68% |
Management Effectiveness
Return on Assets (TTM) 5.65% | Return on Equity (TTM) 10.81% |
Valuation
Trailing PE 27.21 | Forward PE 15.58 | Enterprise Value 11.21B | Price to Sales(TTM) 4.91 |
Enterprise Value 11.21B | Price to Sales(TTM) 4.91 | ||
Enterprise Value to Revenue 5.3 | Enterprise Value to EBITDA 15.89 | Shares Outstanding 206.50M | Shares Floating 204.92M |
Shares Outstanding 206.50M | Shares Floating 204.92M | ||
Percent Insiders 0.48 | Percent Institutions 81.14 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.